Related Experiment Videos
Challenges in tuberculosis screening before TNF-α inhibitors: A case report highlighting gaps in current practice
Aurelie J F Schroë1, Marijke Rutten2, Sami O Simons2
1Department of Respiratory Medicine, Imeldaziekenhuis, Bonheiden, Belgium.
None:
We present the case of a 34-year-old Polish man with a history of axial spondyloarthritis and Crohn's disease, who presented with respiratory and neurological symptoms whilst on TNF-α inhibitors treatment. He subsequently developed a fulminant pulmonary tuberculosis (TB) with cerebral involvement. Treatment was complicated by a paradoxical reaction and respiratory failure requiring intensive care admission. This case highlights the diagnostic challenges associated with TB screening prior to immunosuppressive therapy and underscores the limitations of single-test screening protocols. It further emphasizes that, in immunocompromised patients, both IGRA and TST have reduced sensitivity, and a dual testing strategy with repeated, risk-based screening may improve detection in selected high-risk populations. This case also demonstrates that tuberculosis in immunosuppressed patients can follow a fulminant course, and that early detection and timely initiation of appropriate therapy are essential determinants of clinical outcome.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Therapeutic Drug Monitoring: Affecting Factors
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...